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Effect of Protein Binding on Drug Penetration into Blister Fluid
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The effect of protein binding on drug penetration into blister fluid was evaluated by using cefonicid,
ceftizoxime, and cefotaxime. Drug concentrations in a chamber with a high surface area/volume ratio (i.e.,
paper disk) follow changes in serum more closely than do those in a chamber with a low surface area/volume
ratio. Both the area under the concentration-time cu'rve ratio and the concentration ratio (by the disk method)
for cefonicid were statistically lower than the ratios for ceftizoxime and cefotaxime. The high degree of protein
binding of cefonicid results in the availability of less drug for diffusion to blister fluid than with the
low-protein-binding ceftizoxime and cefotaxime.
Drug concentrations in blister fluid are critical, since most
bacterial infections occur in the interstitial space and not the
intravascular space. Many investigators have tried to corre-
late the penetration of P-lactam antibiotics into interstitial
fluid with the degree to which the drugs bind protein.
However, such studies have yielded disparate results, as
shown by reports of poor cefazolin extravascular penetra-
tion in one study (11, 12) and of good penetration in other
studies (1, 4, 5, 7, 8).
Cefonicid is 98% bound to serum protein and is used for
the treatment of skin and soft tissue infections (3). In view of
the high degree of protein binding of this compound, the
penetration of the drug into blister fluid was compared with
the penetrations of ceftizoxime and cefotaxime (<40%
bound) by using a modified suction blister technique (10).
Six healthy volunteers (four male and two female) be-
tween the ages of 25 and 29 years and weighing 51 to 80 kg
were enrolled in this study. Female volunteers were not
pregnant or receiving oral contraceptives.
Each subject received a single 30-mg/kg (body weight)
dose of cefonicid, ceftizoxime, or cefotaxime on three occa-
sions. A treatment schedule was assigned randomly to each
subject. There was at least 1 week between doses. Drugs
were given by constant intravenous infusion over 5 min into
an antecubital vein via an indwelling intravenous catheter.
Nornmal saline (3 ml) was injected immediately after the
infusion to flush the catheter. Blood samples were obtained
from the cannulus, after discarding the first 2 ml, at 0, 5, 10,
20, 30, 45, 60, 90, 120, 150, 180, 210, 240, 300, 360, 480, 600,
720, and 1,440 min after dosing. Each volunteer had eight
skiii blisters produced on his or her forearm by the modified
suction blister technique previously described by Shyu et al.
(10).
In the protein-binding study, cefonicid standards were
prepared in freshly pooled human serum at 37°C at 450, 400,
350, 300, 250, 175, 150; 125, 100, 75, 50, 25, and 12.5 ,ug/ml.
A portion (1 ml) of the serum sample was transferred into an
Amicon MSP-1 ultrafiltration unit with YMT membranes
* Corresponding author.
t Present address: Department of Metabolism and Pharmacoki-
netics, Bristol-Myers Company, P.O. Box 4755, Syracuse, NY
13221.
immediately after preparation. Ultrafiltration was performed
at 37°C and 1,000 x g for 15 min.
Cefonicid concentrations were determined by a microbio-
logical assay with Bacillus subtilis ATCC 6633 as the test
organism. Serum standards were prepared in pooled serum,
and blister fluid standards were prepared in 50% pooled
serum and 50% phosphate buffer (0.1 M, pH 7.4). Protein-
free filtrate standards were prepared in phosphate buffer (0.1
M, pH 7.4), which was found to produce the same detection
response as protein-free filtrate (data not shown). The assay
limits for cefonicid were 12.5, 6.3, and 0.5 t4g/ml in serum,
blister fluid, and protein-free filtrate samples, respectively.
The assay coefficients of variation between days and within
day were less than 10%.
The area under the concentration-time curve (AUC) ratio
of drug in blister fluid from each subject was calculated as
follows: AUC ratio = AUCbfister/AUCSePJm x 100, where
AUCblister and AUCserum represent the AUCs of blister fluid
and serum, respectively. Both AUCserum and AUCblister
were calculated by the linear trapezoidal rule and estimated
the last concentration in serum to infinity by serum concen-
tration/slope of the elimination phase.
The AUC ratio is a good indicator of the total amount of
drug that reaches an extravascular compartment. To avoid
comparative error in AUC ratio calculations, there must be
enough concentration measurements to characterize the
drug concentration-time profiles. For this reason, the AUC
ratio could not be calculated for cefonicid when the blister
technique was used.
The concentration ratio of drug in blister fluid was calcu-
lated as follows: concentration ratio = (blister concentra-
tion/serum concentration) x 100, where blister concentra-
tion and serum concentration are the simultaneous drug
concentration in blister fluid and serurm, respectively. This
measurement is a valid estimation of penetration into an
extravascular compartment only after distribution to various
body sites is accomplished, i.e., during the elimination
phase. The measurement is also inaccurate if the time lapse
to the elimination phase is prolonged by artifacts in the
sampling method (e.g., skin blister fluid). There are diffi-
culties in determining when the purely elimination phase
begins. For these reasons, this calculation can be applied
only to the results obtained by the paper disk method.
In the concentration range below 175 ,ug/ml, the fraction of
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1. Percentage of bound cefonicid versus total drug concen-
cefonicid bound was 96.0 ± 0.4%. Pronounced nonlinear
binding of cefonicid to serum protein occurred as concentra-
tions exceeded 175 ,ug/ml (Fig. 1). Scatchard plot analysis of
the binding data suggested only one class of binding site. The
number of binding sites and binding affinity constant ob-
tained from this study, assuming the binding protein is
albumin, were 0.95 ± 0.14 and (6.3 ± 2.8) x 104/M,
respectively.
By the paper disk method, the cefonicid blister pharma-
cokinetic profile was similar to the serum pharmacokinetic
profile (Fig. 2A). The cefonicid concentration in blister fluid
at 30 min was 44 ± 15 ,ug/ml. The elimination half-lives in
blister fluid and serum were 4.4 ± 1.0 and 4.1 ± 0.8 h,
respectively. The AUC and concentration ratios were 23.2 ±
1.1 and 26.3 ± 0.9%, respectively.
The protein concentration in blister fluid collected before
administration of the drug and during the experimental
period was 3.9 ± 0.4 g/dl (n = 32). The distribution of
cefonicid into suction blisters was delayed, with peak con-
centrations occurring 5 h postdose (Fig. 2B). The peak
concentration of cefonicid in the blister fluid was 47 ± 10
p.g/ml. The elimination half-lives in blister fluid could not be
determined, since an elimination phase could not be identi-
fied.
The data for ceftizoxime and cefotaxime were previously
published as part of a methodological study (10).
Previous studies have noted the importance of the surface
area/volume (SA/V) ratio of an extravascular compartment
when the pharmacokinetics of drugs in tissue fluid are
evaluated (9, 10, 13). As observed in previous studies, drug
concentrations in fluid spaces with a high SA/V ratio (i.e.,
paper disk) tend to more closely follow changes in the
intravascular space, whereas drug concentrations in spaces
with a low SA/V ratio (i.e., blister fluid) equilibrate more
slowly, i.e., exhibit delayed and depressed peak concentra-
tions (Fig. 2B).
Our data demonstrate that cefonicid is highly bound to
serum proteins. Binding also significantly influences the
pharmacokinetics of this drug in blister fluid, since the fluid
contains a high protein concentration (approximately 50% of
that found in serum). This resulted in a delayed peak drug
concentration in blister fluid (approximately 5 h postdose)
for cefonicid compared with the peaks observed for cefti-
zoxime and cefotaxime, which are less than 40% bound to
plasma proteins (2) (approximately 1 to 1.5 h after the dose;
10). This was consistent with the results of previous studies
which compared drugs with high and low degrees of binding
to serum proteins (6, 9, 14). The crossover of serum and
blister fluid curves with the blister technique presents diffi-
culties in accurately determining the penetration of a drug,
regardless of the degree of protein binding. It is suggested
that those parameters not be calculated from experiments
which use collection devices with low SA/V ratios.
When a device with a high SA/V ratio, i.e., a paper disk,
was used, a parallel between total cefonicid pharmacokinet-
ics in serum and blister fluid was observed (Fig. 2A).
Ceftizoxime and cefotaxime also demonstrated the same
characteristics (10). The peak blister concentrations for all
three compounds were reached within 30 min (the earliest
sampling time), indicating that penetration into blister fluid
was rapid. The drug concentration ratios of cefonicid, cefti-
zoxime, and cefotaxime were 26.3, 35.1, and 30.5, respec-
tively, in simultaneously drawn interstitial fluid and serum
samples (statistically significant, P < 0.05 by the Student t
test). It appears that the high degree of protein binding of
cefonicid decreases its availability to blister fluid and pre-
sumably to interstitial fluid.
In summary, these data demonstrate that despite high
1000
500
I
0
0
z
0-(.)
1000
A
1400600 800
TIME (MIUTES)
B
200 400 600 800 1000 1200 1400
TIME (MINUTES)
FIG. 2. Concentration-time curves for cefonicid in serum (0)
and in blister fluid (0) after a single 30-mg/kg intravenous bolus dose
in a representative volunteer. Blister fluid was obtained by the paper
disk (A) and blister fluid (B) methods.
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binding to serum proteins, total cefonicid concentrations in
blister fluid are inhibitory for many human pathogens (3).
Compared with distribution of drugs with low degrees of
plasma protein binding, such as ceftizoxime and cefotaxime,
the distribution of cefonicid into a fluid with a small SA/V
ratio, e.g. skin blisters, was delayed. Despite nonlinear
serum protein binding after a single dose, this was particu-
larly true in protein-containing fluid spaces with small SA/V
ratios. A high degree of protein binding also made less drug
available to the interstitial fluid than was available with
similar compounds with low-protein-binding properties. This
is probably not a problem when the target microorganism is
extremely susceptible to cefonicid but may be a factor in
microbial eradication for moderately susceptible organisms.
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